Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

This review article discusses safety of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, all of which are approved CD19-directed CAR T-cell therapies for patients with relapsed/refractory large B-cell lymphoma. Common adverse events such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are discussed, as are hemophagocytic lymphohistiocytosis and other events.